ClinicalTrials.gg
Not yet recruitingNCT07833735Updated Sep 22, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of SYS6043 and bevacizumab in Advanced Solid Tumors, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label, safety run-in, dose-expansion and cohort-expansion Phase I/II study designed to evaluate the safety, tolerability, PK profile and preliminary anti-tumor efficacy of SYS6043 (a B7-H3-targeted ADC) in participants with advanced/metastatic solid tumors. The trial consists of two phases: the Phase I component is the safety run-in study, and the Phase II component includes the dose-expansion study and cohort-expansion study.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd. is the lead sponsor of 42 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years (inclusive), as of the date of signing the Form (ICF).
  2. Phase I Safety Run in Cohort: Participants with solid tumors whose disease has or progressed during or following standard of care systemic therapy, or who are intolerant to standard of care therapy and for whom no available standard of care treatment exists.
  3. Phase II Dose expansion Stage: Participants with solid tumors whose disease has relapsed or progressed during or following standard of care systemic therapy, or who are intolerant to standard of care therapy and for whom no available standard of care treatment exists.

    Phase II Cohort Expansion Stage: Participants with or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, with histological subtypes of high grade serous carcinoma or grade 2 3 endometrioid carcinoma:

    1. Cohorts 1/2/3: Platinum sensitive recurrence (platinum sensitive recurrence is defined as disease progression or relapse ≥ 183 days after the last platinum containing chemotherapy).

      Cohort 1: Participants with platinum sensitive recurrence who achieved clinical complete response (CR) or partial response (PR) following platinum containing chemotherapy combined with bevacizumab. A minimum of 3 cycles of bevacizumab plus platinum based chemotherapy are required. For participants who have undergone interval secondary cytoreductive surgery, administration of only 2 cycles of bevacizumab during the final 3 cycles of platinum triplet therapy is permitted. If participants carry germline or somatic BRCA1/2 mutations, prior exposure to PARP inhibitors is required; alternatively, participants may have BRCA wild type or unknown BRCA status. The maximum interval between the last dose of prior triplet therapy (defined as Day 1 of the last cycle of second line platinum containing triplet combination therapy) and Cycle 1 Day 1 (C1D1) of maintenance therapy with bevacizumab or SYS6043 combined with bevacizumab shall be 10 weeks. No clinical evidence of disease progression (by physical examination, imaging, or CA 125) shall be present prior to trial randomization.

      Cohort 2: Participants with platinum sensitive recurrence who achieved clinical CR or PR following platinum containing chemotherapy without bevacizumab. If participants carry germline or somatic BRCA1/2 mutations, prior exposure to PARP inhibitors is required; alternatively, participants may have BRCA wild type or unknown BRCA status. The maximum interval between the last dose of prior triplet therapy (defined as Day 1 of the last cycle of second line platinum containing triplet combination therapy) and C1D1 of SYS6043 maintenance therapy shall be 10 weeks. No clinical evidence of disease progression (by physical examination, imaging, or CA 125) shall be present prior to trial randomization.

      Cohort 3: Participants with platinum sensitive recurrence who have not received prior systemic therapy.

    2. Cohort 4: First line treatment setting (no therapy; newly diagnosed FIGO stage non I disease).
    3. Cohort 5: Participants who achieved CR/PR after first line platinum containing chemotherapy with bevacizumab; BRCA1/2 wild type / HRD negative or unknown status. The maximum interval between the last dose of prior triplet therapy (defined as Day 1 of the last cycle of first line platinum containing triplet combination therapy) and C1D1 of maintenance therapy shall be 10 weeks. No clinical evidence of disease progression (by physical examination, imaging, or CA 125) shall be present prior to trial randomization.
  4. At least one measurable extracranial target lesion per Version 1.1 (for Cohort 3 of Phase II only);
  5. Participant's expected survival ≥ 3 months;
  6. performance status 0-1 with no deterioration within 28 days prior to enrollment;
  7. ≥ 50% demonstrated by ECHO or MUGA performed within 28 days prior to enrollment;
  8. Adequate organ function as defined below, assessed within 7 days prior to enrollment:Major organ function must meet the following criteria within 7 days prior to enrollment:

    1. Complete blood count (no whole blood, red blood cell, or transfusion, and no administration of hematopoietic growth factors [G-CSF or GM-CSF], erythropoietin [EPO], or thrombopoietin [TPO] to correct blood cell counts within 7 days before sampling):i. (ANC) ≥ 1.5 × 10\^9/L;Platelet count (PLT) ≥ 100 × 10\^9/L; (HGB) ≥ 90 g/L.
    2. Blood biochemistry:i. Serum creatinine ≤ 1.5 × ;Serum total (TBIL) ≤ 1.5 × ULN (participants with Gilbert's syndrome may be allowed up to 3 × ULN); (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5.0 × ULN for participants with hepatocellular carcinoma or liver );Serum albumin ≥ 30 g/L.
    3. Coagulation function:

    i. (APTT) and international normalized ratio (INR) ≤ 1.5 × ULN (for participants not receiving anticoagulation therapy; for those on anticoagulation therapy, levels must be within the therapeutic range with stable dose).

  9. Any toxicities related to prior therapy have resolved to version 6.0 grade ≤1 or baseline level, excluding alopecia, fatigue, pigmentation, hypothyroidism stabilized with hormone replacement therapy, grade 2 peripheral neuropathy following chemotherapy, and other toxicities that the investigator deems not to pose a safety risk to participants.
  10. A sufficient from prior anti-tumor therapy is required prior to the first study drug administration.
  11. Willing to provide a previously excised tumor sample or undergo a fresh tumor for the assessment of B7-H3 expression level (if no exist).
  12. Female participants of must have a negative serum pregnancy test within 7 days prior to first administration. Male and female participants with fertility must agree to take adequate measures during the study period and for at least 7 months after the last administration of the drug; During this period, women are not breastfeeding, male participants are not allowed to freeze or donate sperm, and female participants are not allowed to donate eggs or retrieve eggs for personal use.
  13. Capable and willing to comply with the visits and procedures specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participants with non epithelial ovarian carcinoma, clear cell carcinoma, mucinous carcinoma, carcinosarcoma or sarcoma, mixed tumors containing any of the above histologic subtypes, or low grade / borderline ovarian tumors (Phase II expansion cohort only);
  2. Prior exposure to B7 H3 targeted therapy;
  3. Prior treatment with topoisomerase 1 inhibitor based antibody drug conjugates (e.g., trastuzumab deruxtecan);
  4. History of severe cardiac or cerebrovascular disease, e.g., heart failure with Class ≥ 2, acute coronary syndrome (e.g., myocardial infarction, unstable angina) within 6 months prior to screening, acute cerebrovascular events (e.g., , cerebral infarction, cerebral hemorrhage) within 6 months prior to screening;
  5. Mean corrected by Fredericia formula > 470 ms based on three 12 lead tracings; history of severe arrhythmias (e.g., complete left bundle branch block, third degree atrioventricular block, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter; transient atrial fibrillation/atrial flutter excluded);
  6. Inability or unwillingness to discontinue concomitant medications known to prolong the QT interval;
  7. History of interstitial lung disease / non infectious pneumonitis requiring therapy (e.g., non infectious interstitial pneumonitis, pulmonary interstitial fibrosis, severe radiation pneumonitis), or active interstitial lung disease / non infectious pneumonitis at present, or radiological suspicion of such disease at screening;
  8. History of underlying pulmonary disease, including but not limited to pulmonary embolism within 3 months prior to study treatment initiation, severe asthma, severe (COPD), severe restrictive lung disease, other pulmonary impairment, or requirement for supplemental oxygen;
  9. Presence of active pulmonary tuberculosis. Participants who have received adequate anti tuberculosis therapy and completed anti tuberculosis treatment for ≥ 3 months prior to randomization are eligible;
  10. Any disease, connective tissue disease, or inflammatory disorder with documented or suspected pulmonary involvement at screening (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis);
  11. Thrombotic events requiring therapeutic intervention within 6 months prior to screening, including unstable deep vein thrombosis, arterial thrombosis, pulmonary embolism, myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack. Isolated muscular calf vein thrombosis or catheter related thrombosis may be enrolled if assessed as low risk by the Investigator;
  12. Uncontrolled infection requiring intravenous antibacterial, antiviral, or antifungal therapy;
  13. Known (HIV) infection; active syphilis infection (positive treponemal antibody or condition requiring systemic therapy);
  14. Participants with active viral hepatitis: positive surface antigen and/or positive hepatitis B core antibody with HBV DNA ≥ 10 000 copies/mL or 2000 IU/mL; positive serology with HCV RNA above the lower limit of quantitation of the assay;
  15. Spinal cord compression, clinically active , or . Participants with central nervous system (CNS) are eligible if they have received prior CNS directed therapy and have radiologically and neurologically stable disease for at least 4 weeks before first study drug administration (i.e., no new or progressive metastatic lesions on imaging, no corticosteroid requirement, or stable/decreasing corticosteroid dose equivalent to ≤ 10 mg prednisone per day, and asymptomatic). Untreated asymptomatic CNS metastases are permitted if immediate intervention is not deemed necessary by the Investigator;
  16. Active diagnosed within 3 years prior to randomization, except for radically treated basal cell skin carcinoma, squamous cell skin carcinoma, superficial bladder carcinoma, cervical carcinoma in situ, breast carcinoma in situ, or other radically resected in situ malignancies judged eligible by the Investigator;
  17. Moderate or greater pleural, pericardial, or ascitic effusion. Participants may be enrolled if effusion drainage (excluding diagnostic thoracentesis) has been performed and effusion remains stable for at least 2 weeks post drainage;
  18. History of female genital tract fistula, genitourinary fistula, enterovaginal fistula, abdominal wall fistula, gastrointestinal perforation, non healed gastric ulcer, or active gastrointestinal bleeding within 6 months prior to enrollment;
  19. Bowel obstruction, or signs/symptoms of bowel obstruction, or requirement for parenteral nutrition within 1 month prior to study treatment initiation. Participants may proceed to screening if surgical decompression has been performed with complete resolution of obstruction. Prior enteral stent placement with the stent still in situ at screening;
  20. Participants with active bleeding or bleeding diathesis, including known bleeding disorders, coagulopathy, or high bleeding risk tumor involving major blood vessels;
  21. Major surgery within 4 weeks prior to screening ( of any type and variceal procedures within 4 weeks are excluded);
  22. Unhealed wounds, active ulcers, or fractures. Granulating wounds undergoing secondary intention healing without dehiscence or evidence of infection are permitted; wound assessment shall be performed every 3 weeks;
  23. Major traumatic injury within 4 weeks before randomization;
  24. Uncontrolled hypertension despite optimal antihypertensive pharmacotherapy, judged by the Investigator to render bevacizumab based therapy inappropriate;
  25. History or physical exam evidence of central nervous system disorders, including primary brain tumor, seizures uncontrolled by standard medical therapy, brain metastases, or stroke within 5 years before first study treatment. History of severe psychiatric disorders, including but not limited to dementia, depression, seizure disorder, bipolar affective disorder;
  26. Systemic anticoagulation is permitted, with the exception of vitamin K antagonists;
  27. Any history of nephrotic syndrome or nephritic syndrome;
  28. Clinically significant proteinuria: urine protein to creatinine ratio ≥ 1.0, or urine dipstick protein ≥ 2+, or urinalysis protein ≥ 2+. A 24 hour urine collection must demonstrate ≥ 1 g protein/24 h;
  29. Tumor invasion into vital adjacent structures (e.g., mediastinal great vessels, superior vena cava, inferior vena cava, pericardium, heart, trachea, esophagus), or high risk of gastrointestinal / respiratory fistula formation;
  30. Current or recent (within 6 months) major gastrointestinal / respiratory disease or condition, including: history of inflammatory bowel disease; post endoprosthesis placement within gastrointestinal or tracheal lumen; Grade ≥ 2 diarrhea within 2 weeks prior to first study drug administration; radiation enteritis;
  31. Systemic administration of strong inhibitors or inducers, or OATP1B1 / OATP1B3 inhibitors within 14 days prior to first study drug dose, or anticipated continued systemic use of such agents during study treatment;
  32. Known to active pharmaceutical ingredient or of study drug;
  33. Prior or allogeneic stem cell transplantation;
  34. Substance abuse, or any other medical condition that, in the Investigator's opinion, may increase participant safety risk, interfere with study participation, or confound study assessments;
  35. Planned administration, or receipt of live vaccine within 4 weeks before first study drug dose;
  36. Any participant with other severe medical conditions, significant laboratory abnormalities, or poor adherence that may increase risks of study participation or confound study results, and who is deemed unsuitable for this study by the Investigator. Participants with local or systemic non-malignant disorders, or tumor-related sequelae/symptoms associated with substantial medical risk and/or uncertainty in survival assessment, e.g., tumor-related leukemoid reaction (white blood cell count > 20 × 10⁹/L), cachexia.
Terms in these criteria, in plain language(42)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    SYS6043+ bevacizumab

    In this group, participants will receive SYS6043 with bevacizumab;

    Drug: SYS6043 · Drug: bevacizumab

  • Experimental
    SYS6043+ carboplatin

    In this group, participants will receive SYS6043 with carboplatin

    Drug: SYS6043 · Drug: carboplatin

  • Experimental
    SYS6043 + carboplatin + bevacizumab

    In this froup, participants will receive SYS6043 with carboplatin and bevacizumab

    Drug: SYS6043 · Drug: bevacizumab · Drug: carboplatin

  • Experimental
    SYS6043

    In this group, participants will receive SYS6043 ;

    Drug: SYS6043

  • Experimental
    Bevacizumab

    In this group, participants will receive bevacizumab ;

    Drug: bevacizumab

Interventions

  • Participants in the experimental group will receive SYS6043, Q3W administered on Day 1 of each cycle..

  • Participants in the experimental group will receive bevacizumab Q3W administered on Day 1 of each cycle.

  • Participants in the experimental group will receive carboplatin Q3W administered on Day 1 of each cycle.

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs) -(Phase I: Safety Run-in Study)

    Time frame: 21 days for Arm 1-3.

  2. Incidence of adverse events (AEs) and serious adverse events (SAEs) assessed by CTCAE 6.0-(Phase I: Safety Run-in Study)

    Time frame: 2 years

  3. Maximum tolerated dose (MTD) (if any) ) of SYS6043 with or without bevacizumab with or without carboplatin-(Phase I: Safety Run-in Study)

    Time frame: Up to 1year

  4. Recommended phase 2 dose (RP2D) of SYS6043 with or without bevacizumab with or without carboplatin-(Phase I: Safety Run-in Study)

    Time frame: 2 years

  5. Incidence of adverse events (AEs) and serious adverse events (SAEs) assessed by CTCAE 6.0-(Phase II: Dose-expansion Study)

    Time frame: Up to 1year

  6. PFS rate assessed by RECIST Version 1.1(Phase II: Cohort-expansion Study)

    Time frame: 2 years

Secondary outcomes

  1. PFS based on RECIST v1.1-(Phase I: Safety Run-in Study)

    Time frame: 2 years

  2. ORR based on RECIST v1.1-(Phase I: Safety Run-in Study)

    Time frame: 2 years

  3. DoR based on RECIST v1.1-(Phase I: Safety Run-in Study)

    Time frame: 2 years

  4. DCR by Blinded Independent Central Review (BICR) based on RECIST v1.1-(Phase I: Safety Run-in Study)

    Time frame: 2 years

  5. TTR based on RECIST v1.1-(Phase I: Safety Run-in Study)

    Time frame: 2 years

  6. OS-(Phase I: Safety Run-in Study)

    Time frame: 2 years

  7. Number of Participants With Anti-Drug Antibodies (ADA): Incidence, titer of anti-SYS6043 antibodies, and incidence of neutralizing antibodies (if applicable) -(Phase I: Safety Run-in Study)

    Time frame: 2 years

  8. Serum concentrations of toxin-bound antibody of SYS6043-(Phase I: Safety Run-in Study)

    Time frame: 2 years

  9. Serum concentrations of total antibody of SYS6043-(Phase I: Safety Run-in Study)

    Time frame: 2 years

  10. Association between B7-H3 expression level and efficacy-(Phase I: Safety Run-in Study)

    Time frame: 2 years

  11. Association between B7-H3 expression level and safety-(Phase I: Safety Run-in Study)

    Time frame: 2 years

  12. PFS based on RECIST v1.1-(Phase II: Dose expansion Study)

    Time frame: 2 years

  13. ORR based on RECIST v1.1-( Phase II: Dose expansion Study)

    Time frame: 2 years

  14. DoR based on RECIST v1.1-( Phase II: Dose expansion Study)

    Time frame: 2 years

  15. DCR by Blinded Independent Central Review (BICR) based on RECIST v1.1-( Phase II: Dose expansion Study)

    Time frame: 2 years

  16. TTR based on RECIST v1.1-( Phase II: Dose expansion Study)

    Time frame: 2 years

  17. OS-( Phase II: Dose expansion Study)

    Time frame: 2 years

  18. Number of Participants With Anti-Drug Antibodies (ADA): Incidence, titer of anti-SYS6043 antibodies, and incidence of neutralizing antibodies (if applicable) -( Phase II: Dose expansion Study)

    Time frame: 2 years

  19. Serum concentrations of toxin-bound antibody of SYS6043-( Phase II: Dose expansion Study)

    Time frame: 2 years

  20. Serum concentrations of total antibody of SYS6043-( Phase II: Dose expansion Study)

    Time frame: 2 years

  21. Association between B7-H3 expression level and efficacy-( Phase II: Dose expansion Study)

    Time frame: 2 years

  22. Association between B7-H3 expression level and safety-( Phase II: Dose expansion Study

    Time frame: 2 years

  23. PFS based on RECIST v1.1-(Phase II: Cohort expansion Study)

    Time frame: 2 years

  24. ORR based on RECIST v1.1-( Phase II: Cohort expansion Study)

    Time frame: 2 years

  25. DoR based on RECIST v1.1-( Phase II: Cohort expansion Study)

    Time frame: 2 years

  26. DCR based on RECIST v1.1-( Phase II: Cohort expansion Study)

    Time frame: 2 years

  27. TTR based on RECIST v1.1-( Phase II: Cohort expansion Study)

    Time frame: 2 years

  28. CA-125 response rate assessed by the investigator-( Phase II: Cohort expansion Study)

    Time frame: 2 years

  29. OS-( Phase II: Cohort expansion Study)

    Time frame: 2 years

  30. Number of Participants With Anti-Drug Antibodies (ADA): Incidence, titer of anti-SYS6043 antibodies, and incidence of neutralizing antibodies (if applicable) -( Phase II: Cohort expansion Study)

    Time frame: 2 years

  31. Serum concentrations of toxin-bound antibody of SYS6043-( Phase II: Cohort expansion Study)

    Time frame: 2 years

  32. Serum concentrations of total antibody of SYS6043-( Phase II: Cohort expansion Study)

    Time frame: 2 years

  33. Association between B7-H3 expression level and efficacy-(Phase II: Cohort expansion Study)

    Time frame: 2 years

  34. Association between B7-H3 expression level and safety-(Phase II: Cohort expansion Study)

    Time frame: 2 years

  35. Association between HRR related gene alterations in tumor tissue and efficacy(Phase II: Cohort expansion Study)

    Time frame: 2 years

  36. Association between HRR related gene alterations in tumor tissue and safety(Phase II: Cohort expansion Study)

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 22, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
Oct 15, 2028
CompletionEst.
Oct 15, 2029
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07833735
Responsible party
Sponsor
First posted
Sep 22, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Oct 15, 2028 (estimated)
Completion
Oct 15, 2029 (estimated)
Last update
Sep 22, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
031169085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 · Bevacizumab

Start the discussion